Send to a Friend Font Size: Increase Decrease

RXRX and RLYB Related Headlines

Jul 8, 2025 08:03AM Recursion (RXRX) acquires full rights to oral HPP treatment REV102
Jul 8, 2025 08:00AM Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

RXRX and RLYB Related Press Releases

Jul 8, 2025 08:00AM Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

RXRX and RLYB Related SEC Filings